Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials

Helen J. MacKay, Douglas A. Levine, Victoria L. Bae-Jump, Daphne W. Bell, Jessica N. McAlpine, Alessandro Santin, Gini F. Fleming, David G. Mutch, Kenneth P. Nephew, Nicolas Wentzensen, Paul J. Goodfellow, Oliver Dorigo, Hans W. Nijman, Russell Broaddus and Elise C. Kohn _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:84579-84594. https://doi.org/10.18632/oncotarget.19961

Metrics: PDF 2360 views  |   HTML 4769 views  |   ?  


Helen J. MacKay1, Douglas A. Levine2, Victoria L. Bae-Jump3, Daphne W. Bell4, Jessica N. McAlpine5, Alessandro Santin6, Gini F. Fleming7, David G. Mutch8, Kenneth P. Nephew9, Nicolas Wentzensen10, Paul J. Goodfellow11, Oliver Dorigo12, Hans W. Nijman13, Russell Broaddus14 and Elise C. Kohn15

1Division of Medical Oncology & Hematology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

2Division of Gynecologic Cancer, Department of OB/GYN, NYU Langone Laura and Isaac Perlmutter Cancer Center, New York, NY, United States

3Division of Gynecologic Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, CA, United States

4Reproductive Cancer Genetics Section, Cancer Genetics and Comparative Genomics Branch, National Human Genome Research Institute/NIH, MSC 8000, Bethesda, ML, United States

5University of British Columbia & BC Cancer Agency, Division of Gynecologic Oncology, Vancouver, British Columbia, Canada

6Department of Gynecology, Obstetrics and Reproductive Sciences, Yale School of Medicine, New Haven, CT, United States

7Section of Hematology-Oncology, Department of Medicine, The University of Chicago, Chicago, IL, United States

8Department of Obstetrics & Gynecology, Washington University School of Medicine, St. Louis, MO, United States

9Medical Sciences Program, Indiana University School of Medicine, Bloomington, IN, United States

10Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, ML, United States

11James Comprehensive Cancer Center and The Department of Obstetrics and Gynecology, Ohio State University, Columbus, OH, United States

12Division Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford, CA, United States

13Department of Gynecology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

14Department of Pathology, Unit 85, University of Texas M.D. Anderson Cancer Center, Houston, TX, United States

15Clinical Investigations Branch of The Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, ML, United States

Correspondence to:

Elise C. Kohn, email: [email protected]

Keywords: endometrial cancer, molecular targets

Received: March 03, 2017    Accepted: May 15, 2017    Published: August 03, 2017


The incidence and mortality rates from endometrial cancer are increasing. There have been no new drugs approved for the treatment of endometrial cancer in decades. The National Cancer Institute, Gynecologic Cancer Steering Committee identified the integration of molecular and/or histologic stratification into endometrial cancer management as a top strategic priority. Based on this, they convened a group of experts to review the molecular data in this disease. Here we report on the actionable opportunities and therapeutic directions identified for incorporation into future clinical trials.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19961